Nasdaq-listed biopharmaceutical firm China Biologic Products Holdings suspended the trading of its shares on Wall Street on Wednesday, after the completion of a take-private deal sponsored by a Chinese buyout group that valued the firm at about $4.76 billion.
The consortium is led by entities affiliated with Centurium Capital, a private equity (PE) firm founded by former Warburg Pincus partner David Li. Other investors in the consortium include Chinese PE company CITIC Capital; Asia-focused Hillhouse Capital; and V-Sciences Investments, a subsidiary of Singapore’s Temasek Holdings, among others.
